ヴィーヴヘルスケアがギリアドに対して特許権侵害訴訟を開始
ViiV Healthcare files patent infringement litigation against Gilead Sciences Inc. over bictegravir 07 February 2018 ヴィーヴヘルスケアがギリアドに対して 抗HIV薬 ビクテグラビルに関する特許権侵害訴訟を開始した。 ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that it has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United States and Canada. The United States case is filed in the U.S. District Court for the District of Delaware and the patent is U.S patent No. 8,129,385. The Canadian case is filed in the Canadian Federal Court in Toronto and the patent is Canadian Patent No. 2,606,282. ViiV Healthcare will seek to prove that Gilead Sciences Inc’s triple combination HIV drug containing the HIV integrase inhibitor bictegravir infringes ViiV Healthcare’s patent covering ViiV Healthcare’s dolutegravir and many other compounds that include dolutegravir’s unique chemical scaffold.